Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Case Rep Cardiol ; 2021: 6623119, 2021.
Article in English | MEDLINE | ID: mdl-33927902

ABSTRACT

Adult intensivists have increasing exposure to individuals with congenital diseases surviving into adulthood. Solid knowledge bases and early recognition of the possible sequelae of congenital disorders are crucial in caring for these patients. We present a challenging case of shock and relapse of Diamond-Blackfan anemia in a 42-year-old man lost to follow-up for 18 years and highlighted the importance of healthcare transitions into adulthood and the challenges faced by health care systems to develop new strategies successfully transitioning complex pediatric patients to adult care.

2.
Am J Clin Oncol ; 41(3): 218-222, 2018 03.
Article in English | MEDLINE | ID: mdl-26650780

ABSTRACT

PURPOSE: In 2010, a new study published by the National Lung Screening Trial showed a 20% reduction in mortality for those patients screened with low-dose computed topography (CT) versus x-ray. Recently, the Centers of Medicare and Medicaid have agreed to cover this service for those patients who meet the screening criteria. We compare the outcomes and costs associated with developing and implementing a lung cancer screening program. MATERIALS AND METHODS: One thousand sixty-five patients were screened from January 2014 to December 2014. These patients were screened on a low-dose CT screening protocol throughout Beaumont Health System. The American College of Radiology Lung Imaging Reporting and Data System (Lung-RADS) were used to assign the score for each patient. Screening eligibility criteria were based on the National Comprehensive Cancer Network guidelines. Downstream activity and revenue was determined after initial low-dose CT screening. RESULTS: At 1 year, 20 patients (1.6%) were diagnosed with lung cancer and another 15 patients were diagnosed with another form of cancer after screening. The median age, packs per day, and pack years smoked for all patients was 63, 1.0, and 39.0 years, respectively. Lung-RADS scores for all patients was 18% (1), 24.1% (2), 6.3% (3), and 5.4% (4). The net revenue for all activity after screening was $3.2 million. CONCLUSIONS: The establishment of a low-dose CT lung cancer screening program improved the ability to screen patients as demonstrated by the number of patients screened and those diagnosed with a malignancy. These findings were also consistent with the findings from the National Lung Screening Trial study.


Subject(s)
Early Detection of Cancer/economics , Early Detection of Cancer/methods , Lung Neoplasms/diagnosis , Aged , Female , Humans , Male , Mass Screening/economics , Mass Screening/methods , Middle Aged , Tomography, X-Ray Computed/economics , Tomography, X-Ray Computed/methods , United States
3.
Am J Physiol Lung Cell Mol Physiol ; 301(5): L683-92, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21840960

ABSTRACT

In acute and chronic lung disease, widespread disruption of tissue architecture underlies compromised pulmonary function. Pulmonary fibroblasts have been implicated as critical effectors of tissue-destructive extracellular matrix (ECM) remodeling by mobilizing a spectrum of proteolytic enzymes. Although efforts to date have focused on the catabolism of type I collagen, the predominant component of the lung interstitial matrix, the key collagenolytic enzymes employed by pulmonary fibroblasts remain unidentified. Herein, membrane type-1 matrix metalloprotease (MT1-MMP) is identified as the dominant and direct-acting protease responsible for the type I collagenolytic activity mediated by both mouse and human pulmonary fibroblasts. Furthermore, MT1-MMP is shown to be essential for pulmonary fibroblast migration within three-dimensional (3-D) hydrogels of cross-linked type I collagen that recapitulate ECM barriers encountered in the in vivo environment. Together, these findings demonstrate that MT1-MMP serves as a key effector of type I collagenolytic activity in pulmonary fibroblasts and earmark this pericellular collagenase as a potential target for therapeutic intervention.


Subject(s)
Asthma/metabolism , Extracellular Matrix/metabolism , Fibroblasts , Lung/metabolism , Matrix Metalloproteinase 14/metabolism , Pulmonary Fibrosis/metabolism , Airway Remodeling , Animals , Asthma/pathology , Asthma/physiopathology , Cell Movement , Chronic Disease , Collagen Type I , Extracellular Matrix/pathology , Fibroblasts/cytology , Fibroblasts/metabolism , Gene Silencing/drug effects , Humans , Hydrogels , Lung/pathology , Lung/physiopathology , Matrix Metalloproteinase 1/metabolism , Mice , Mice, Knockout , Microscopy, Confocal , Primary Cell Culture , Protein Binding , Pulmonary Fibrosis/pathology , Pulmonary Fibrosis/physiopathology , RNA, Small Interfering/pharmacology , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...